Biogen (NASDAQ:BIIB) Issues Earnings Results, Misses Expectations By $0.24 EPS

Biogen (NASDAQ:BIIB) posted its quarterly earnings results on Thursday. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.26 by ($0.24), Zacks reports. Biogen had a net margin of 16.87% and a return on equity of 14.98%. The company had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. During the same period in the prior year, the company posted $3.67 EPS. Biogen’s quarterly revenue was up 6.2% on a year-over-year basis. Biogen updated its FY 2025 guidance to 14.500-15.500 EPS.

Biogen Price Performance

NASDAQ BIIB opened at $123.53 on Friday. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $238.00. The stock’s 50-day moving average is $130.58 and its two-hundred day moving average is $147.04. The firm has a market cap of $18.08 billion, a P/E ratio of 11.04, a price-to-earnings-growth ratio of 1.51 and a beta of 0.13. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90.

Insider Transactions at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BIIB shares. William Blair reaffirmed an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. Wells Fargo & Company cut their price objective on Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a report on Thursday, February 13th. HC Wainwright decreased their target price on shares of Biogen from $241.00 to $187.00 and set a “buy” rating for the company in a report on Friday. Citigroup cut their price target on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Finally, Morgan Stanley decreased their price objective on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. Twenty analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $195.85.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.